Photo: Juliana Thomas
Data from a clinical trial shows that an investigational personalized mRNA cancer vaccine, in combination with the immunotherapy pembrolizumab, is effective against melanoma. In people who received the vaccine, the risk of recurrence or death was reduced by 44 percent compared to those who received pembrolizumab alone.
Jeffrey S. Weber, MD, PhD, deputy director of 秘密研究所 Langone Health鈥檚 Perlmutter Cancer Center, was principal investigator of the phase 2b study.
鈥淭hese findings also provide the first randomized evidence that a personalized neoantigen approach may be beneficial in melanoma,鈥 Dr. Weber, also the Laura and Isaac Perlmutter Professor of Oncology in the at 秘密研究所 Grossman School of Medicine, tells Fortune.
Read more from .
